HealthEquity (NASDAQ:HQY) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

by · The Markets Daily

HealthEquity (NASDAQ:HQY – Get Free Report) had its price target boosted by equities research analysts at JPMorgan Chase & Co. from $126.00 to $129.00 in a research report issued on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target points to a potential upside of 36.49% from the stock’s current price.

Other equities research analysts also recently issued reports about the stock. Jefferies Financial Group increased their price objective on shares of HealthEquity from $130.00 to $134.00 and gave the stock a “buy” rating in a research note on Wednesday, September 3rd. Citizens Jmp upped their price target on shares of HealthEquity from $117.00 to $122.00 and gave the stock a “market outperform” rating in a report on Thursday. BMO Capital Markets initiated coverage on shares of HealthEquity in a research report on Thursday, November 13th. They set a “market perform” rating and a $100.00 price target on the stock. KeyCorp lowered their price objective on shares of HealthEquity from $125.00 to $120.00 and set an “overweight” rating for the company in a research report on Wednesday, October 8th. Finally, BTIG Research restated a “buy” rating and set a $130.00 target price on shares of HealthEquity in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, HealthEquity has a consensus rating of “Moderate Buy” and an average target price of $120.43.

View Our Latest Research Report on HQY

HealthEquity Trading Down 1.2%

Shares of NASDAQ:HQY opened at $94.51 on Thursday. The business’s 50 day simple moving average is $96.37 and its 200 day simple moving average is $96.85. HealthEquity has a 1 year low of $74.07 and a 1 year high of $116.65. The company has a debt-to-equity ratio of 0.46, a current ratio of 4.13 and a quick ratio of 4.23. The company has a market capitalization of $8.07 billion, a P/E ratio of 43.35, a P/E/G ratio of 1.38 and a beta of 0.18.

HealthEquity (NASDAQ:HQY – Get Free Report) last released its earnings results on Wednesday, December 3rd. The company reported $1.01 earnings per share for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. The firm had revenue of $322.16 million during the quarter, compared to the consensus estimate of $320.92 million. HealthEquity had a return on equity of 12.94% and a net margin of 14.86%.The company’s revenue was up 7.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.78 EPS. HealthEquity has set its FY 2026 guidance at 3.870-3.950 EPS. On average, research analysts anticipate that HealthEquity will post 2.32 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Michael Henry Fiore sold 1,781 shares of the firm’s stock in a transaction on Tuesday, October 7th. The stock was sold at an average price of $88.21, for a total transaction of $157,102.01. Following the sale, the executive vice president owned 49,795 shares of the company’s stock, valued at $4,392,416.95. This trade represents a 3.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Delano Ladd sold 1,500 shares of the business’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $104.56, for a total value of $156,840.00. Following the sale, the executive vice president owned 75,479 shares in the company, valued at $7,892,084.24. This represents a 1.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 10,781 shares of company stock worth $1,016,707 in the last 90 days. Company insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On HealthEquity

Several large investors have recently bought and sold shares of HQY. Xponance Inc. boosted its position in HealthEquity by 0.8% during the third quarter. Xponance Inc. now owns 12,265 shares of the company’s stock valued at $1,162,000 after acquiring an additional 102 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of HealthEquity by 2.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,787 shares of the company’s stock valued at $397,000 after purchasing an additional 108 shares during the period. Advisors Asset Management Inc. lifted its stake in shares of HealthEquity by 4.7% in the 2nd quarter. Advisors Asset Management Inc. now owns 2,437 shares of the company’s stock valued at $255,000 after purchasing an additional 110 shares during the period. Fiduciary Trust Co boosted its position in shares of HealthEquity by 3.4% during the 3rd quarter. Fiduciary Trust Co now owns 3,669 shares of the company’s stock valued at $348,000 after purchasing an additional 120 shares in the last quarter. Finally, Ieq Capital LLC grew its stake in HealthEquity by 4.4% during the first quarter. Ieq Capital LLC now owns 2,945 shares of the company’s stock worth $260,000 after purchasing an additional 123 shares during the period. 99.55% of the stock is currently owned by institutional investors.

About HealthEquity

(Get Free Report)

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

Featured Stories